Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 190

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Blood (2025) 146 (20): 2443–2456.

https://doi.org/10.1182/blood.2024027822

Published: 2025

Includes: Supplemental data

Journal Articles

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood (2025) 146 (19): 2293–2305.

https://doi.org/10.1182/blood.2025028730

Published: 2025

Includes: Supplemental data

Journal Articles

The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML

Silvia Schäfer, Pascal Fichtel, Silke Brilloff, Sandra Küchler, Elahe Rahimian, Vida Kufrin, Ekaterina Longvinova, Claudia Ball, Hanno Glimm, Denis Schewe, Malte Von Bonin, Martin Bornhäuser, Alexander Wurm, Marius Bill

Blood (2025) 146 (Supplement 1): 5022.

https://doi.org/10.1182/blood-2025-5022

Published: 2025

Journal Articles

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Jan-Niklas Eckardt, Ishan Srivastava, Chethan Babu, Sebastian Riechert, Tim Schmittmann, Susann Winter, Martin Schneider, Markus Badstübner, Ann-Kathrin Eisfeld, Haley Roberts, Christoph Röllig, Martin Bornhäuser, Jan Moritz Middeke, Andrew Srisuwananukorn

Blood (2025) 146 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2025-2558

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Jan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, Susann Winter, Tim Schmittmann, Sebastian Riechert, Miriam Eva Helena Gediga, Anas Shekh Sulaiman, Martin M. K. Schneider, Freya Schulze, Christian Thiede, Katja Sockel, Frank P. Kroschinsky, Christoph Röllig, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2024-198486

Published: 2024

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Blood (2024) 144 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2024-200237

Published: 2024

Journal Articles

ACSL4 -Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A -Rearranged Acute Myeloid Leukemia

Silvia Schäfer, Lola Schmitz-Hübsch, Mehak Nihal Shaikh, Silke Brilloff, Elahe Rahimian, Vida Kufrin, Sandra Küchler, Maria Fedorova, Dominic Helm, Claudia R Ball, Martin Bornhäuser, Hanno Glimm, Meritxell Alberich Jorda, Marius Bill, Alexander A Wurm

Blood (2024) 144 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2024-210089

Published: 2024

Journal Articles

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Dante Adami, Sebastian Riechert, Tim Schmittmann, Markus Badstübner, Karsten Wendt, Stefani Barbara Parmentier, Katja Sockel, Frank P. Kroschinsky, Martin Bornhäuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2024) 144 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2024-205235

Published: 2024

Journal Articles

Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress

Blood (2024) 144 (Supplement 1): 944.

https://doi.org/10.1182/blood-2024-200108

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Jan-Niklas Eckardt, Ishan Srivastava, Yeqiao Xu, Kellen B Gil, Andrea A. Osypuk, Zenggang Pan, Martin M. K. Schneider, Freya Schulze, Karsten Wendt, Susann Winter, Martin Bornhäuser, Daniel A. Pollyea, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2024-206776

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

ACSL4 -Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A -Rearranged Acute Myeloid Leukemia

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only